Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283-94.,Engert A, Fanale M, Santoro A, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full release after extended follow-up of the multicohort multicenter phase 2 CHECKMATE 205 trial. EHA 2017, abstract S412.
Recombinant ADAMTS13 bij congenitale trombotische trombocytopenische purpura
sep 2024 | Benigne hematologie